Juno Therapeutics Analysis
Juno Therapeutics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Juno Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Juno Therapeutics is worth, separate from its market price. There are two main types of Juno Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Juno Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Juno Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Juno Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Juno Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Juno Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Juno Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Juno |
Juno Stock Analysis Notes
About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.39. Juno Therapeutics had not issued any dividends in recent years. Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington. Juno Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 589 people. To learn more about Juno Therapeutics call Hans Bishop at 206 582-1600 or check out www.junotherapeutics.com.Juno Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Juno Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Juno Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Juno Therapeutics is not yet fully synchronised with the market data | |
| Juno Therapeutics has some characteristics of a very speculative penny stock | |
| Juno Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 106.56 M. Net Loss for the year was (353.85 M) with profit before overhead, payroll, taxes, and interest of 111.87 M. | |
| Juno Therapeutics currently holds about 927.53 M in cash with (201.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.18. | |
| Over 81.0% of the company shares are owned by institutional investors |
Juno Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 10.1 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Juno Therapeutics's market, we take the total number of its shares issued and multiply it by Juno Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Juno Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Juno Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Juno Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Juno Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Howard Pien over a year ago Acquisition by Howard Pien of 675 shares of Juno Therapeutics subject to Rule 16b-3 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Juno Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Juno Stock
If you are still planning to invest in Juno Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Juno Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |